B
Bullisch
Bullisch · 25%SUPN
$33.77
Szenariopreis
$40.700
-1.327 (-3.26%)Zum Schluss
Loading chart…
- Hoch
- 41.950
- Eröffnung
- 41.680
- Volumengewichteter Durchschnittskurs
- 40.87
- Volumen
- 1.16M
- Marktkap.
- 1.48B
- Tief
- 39.958
- Umsatz
- 47.38M
- EV/EBITDA, TTM
- 32.85
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
KI-Analyse of Supernus Pharmaceuticals Inc (SUPN)
HaltenSupernus Pharmaceuticals Inc is currently not a strong buy due to significant recent losses and negative technical indicators. The current price is $37.88, and the stock has a 5-day change of -11.23%. Additionally, the RSI is extremely low at 13.38, indicating oversold conditions, but this also suggests potential for a rebound. However, the company reported a net loss exceeding $58 million in Q2 2026, contrasting sharply with a net income of $22.5 million in Q2 2025, highlighting ongoing financial struggles. The main risk is the insider selling, which increased by 2510.70% over the last month, signaling a lack of confidence among insiders. Therefore, while the stock may have potential long-term upside due to the merger with Indivior, the current financial and technical indicators suggest a hold position for now.
Analystenbewertungen (8)
+50.69% Aufwärtspotenzial
Kaufen
6 Kaufen
2 Halten
0 Verkaufen
Aktuell: 40.70
Tief
55.00
Durchschnitt
61.33
Hoch
65.00
Cantor Fitzgerald
Übergewichten
$67
2026-07-09
Cantor Fitzgerald
2026-07-09
Kursziel
$67
Übergewichten
TD Cowen
Kaufen
$65
2026-02-25
TD Cowen
2026-02-25
Kursziel
$65
Kaufen
Stifel
Halten
$55
2025-12-19
Stifel
2025-12-19
Kursziel
$55
Halten
TD Cowen
Kaufen
$60
2025-10-23
TD Cowen
2025-10-23
Kursziel
$60
Kaufen
Cantor Fitzgerald
Übergewichten
$63
2025-09-30
Cantor Fitzgerald
2025-09-30
Kursziel
$63
Übergewichten
Bewertungskennzahlen
Das aktuelle erwartete KGV von Supernus Pharmaceuticals Inc (SUPN) beträgt 20.16, verglichen mit dem 5-Jahres-Durchschnitt von 20.51.
Alphio-AI-Kursszenarien für SUPN
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die SUPN halten
Event-Zeitleiste
News
8.510-22NewsfilterSupernus Secures Orphan Drug Exclusivity for ONAPGO
8.510-22NewsfilterMSG Rangers and Huron Consulting Set to Join S&P SmallCap 600 Index
- 9.510-19Newsfilter
Supernus Pharmaceuticals to Report Q3 2026 Financial Results
7.009-25PRnewswireInvestor Rights Law Firm Investigates Multiple Companies
- 1.009-02Newsfilter
Supernus Pharmaceuticals Announces September Investor Conference Participation
SUPN FAQ – beantwortet von Alphio AI
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Supernus Pharmaceuticals Inc is currently not a strong buy due to significant recent losses and negative technical indicators. The current price is $37.88, and the stock has a 5-day change of -11.23%. Additionally, the RSI is extremely low at 13.38, indicating oversold conditions, but this also suggests potential for a rebound. However, the company reported a net loss exceeding $58 million in Q2 2026, contrasting sharply with a net income of $22.5 million in Q2 2025, highlighting ongoing financial struggles. The main risk is the insider selling, which increased by 2510.70% over the last month, signaling a lack of confidence among insiders. Therefore, while the stock may have potential long-term upside due to the merger with Indivior, the current financial and technical indicators suggest a hold position for now.
8 analysts cover SUPN: 6 rate it Buy, 2 Hold and 0 Sell. The average price target is 61.33.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.